{"id":"W2561629989","doi":"10.1182/blood.v112.11.3239.3239","title":"Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Homoharringtonine; Imatinib; Internal medicine; Adverse effect; Dasatinib; Myeloid leukemia; Imatinib mesylate; Phases of clinical research; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003729232,0.0003443702,0.0006886732,0.0001935021,0.0001974564,0.000008154847,0.000209333,0.00009150658,0.00002088509],"category_scores_gemma":[0.0002791584,0.0002293178,0.00007142385,0.0003869279,0.0002169965,0.0001407497,0.0001201182,0.0002662165,0.000002416637],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007577349,"about_ca_system_score_gemma":0.0005285939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001009145,"about_ca_topic_score_gemma":0.001387376,"domain_scores_codex":[0.9972949,0.000198749,0.000943171,0.000544864,0.0006277678,0.0003905546],"domain_scores_gemma":[0.9979856,0.0002449802,0.0005706854,0.0008476871,0.0002113097,0.0001397293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3182307,0.1548897,0.1050125,0.002327067,0.005662396,0.0139368,0.1231486,0.002948906,0.1271242,0.00003209899,0.0001445397,0.1465424],"study_design_scores_gemma":[0.4518016,0.06212974,0.4384879,0.0008782356,0.001366933,0.000603765,0.001256266,0.002530262,0.04038404,0.000002632215,0.0001000896,0.0004585753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968646,0.0003237437,0.000004292026,0.0000887989,0.00003005468,0.002284141,0.0001108876,0.00003769401,0.0002558556],"genre_scores_gemma":[0.9989293,0.0001010918,0.0005399,0.00002041222,0.00004153781,0.00003203682,0.0001747613,0.00004798722,0.0001129712],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3334754,"threshold_uncertainty_score":0.9351308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00963936395558686,"score_gpt":0.2564835968646108,"score_spread":0.2468442329090239,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}